rotigotine

CLINICAL USE

Treatment of Parkinson’s disease

DOSE IN NORMAL RENAL FUNCTION

2–8 mg every 24 hours With levodopa: max 16 mg every 24 hours

PHARMACOKINETICS

Molecular weight :315.5

%Protein binding :92

%Excreted unchanged in urine : 71

Volume of distribution (L/kg) :84

half-life – normal/ESRD (hrs) :5–7/Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unlikely to be dialysed. Dose as in normal renal function

HD :Not dialysed. Dose as in normal renal function

HDF/high flux :Unknown dialysability. Dose as in normal renal function

CAV/VVHD :Unknown dialysability. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Antipsychotics: avoid concomitant use (antagonism of effect)Metoclopramide: avoid concomitant use (antagonism of effect)

ADMINISTRATION

Reconstition

–

Route

Topical

Rate of Administration

–

Comments

–

OTHER INFORMATION

Discontinue gradually at a rate of 2 mg/24 hours, every other day
Apply to intact skin on the abdomen, thigh, hip, flank, shoulder or upper armIf a patch falls off replace with a new one Backing layer contains aluminium and should be removed prior to MRIs or cardioversionRotigotine is being investigated for its use in restless legs syndrome.

Tags: post-by-auto-php